LEVOPHED Drug Patent Profile

Which patents cover Levophed, and what generic alternatives are available?

Levophed is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in LEVOPHED is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levophed

A generic version of LEVOPHED was approved as norepinephrine bitartrate by MEITHEAL on March 3^rd, 2003.

Summary for LEVOPHED

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LEVOPHED

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	LEVOPHED	norepinephrine bitartrate	INJECTABLE;INJECTION	007513-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes

Levophed Investment Analysis: Norepinephrine Patent Status, Market Fundamentals, and Generic Risk

Last updated: July 31, 2026

Levophed is Pfizer’s branded norepinephrine bitartrate injection, used to raise blood pressure in acute hypotensive states, including septic shock. Its core investment profile is defensive rather than growth-oriented: the product has no meaningful remaining patent exclusivity, faces generic competition, and operates in a hospital injectable market where supply reliability and manufacturing capacity matter more than brand pricing.

The principal investment exposure is therefore tied to norepinephrine supply, contract manufacturing, hospital purchasing contracts, and drug-shortage dynamics. Levophed itself has limited ability to support premium pricing or pharmaceutical-style patent returns.

What is Levophed and how does it work?

Levophed is an injectable formulation of norepinephrine bitartrate, the salt form of norepinephrine. Norepinephrine is an alpha-adrenergic and beta-adrenergic agonist that produces vasoconstriction and increases blood pressure. The FDA labeling identifies the product for restoring blood pressure in adults with severe, acute hypotension [1].

Attribute	Levophed
Active ingredient	Norepinephrine bitartrate
Pharmacologic class	Vasopressor; adrenergic agonist
Route	Intravenous infusion
Primary use	Acute severe hypotension and septic shock
Dosage form	Sterile injectable solution or concentrate, depending on presentation
Reference company	Pfizer
FDA application	NDA 007513
Market type	Hospital injectable and critical-care product
Patent profile	Legacy product; no meaningful current composition-of-matter exclusivity

Levophed is administered in hospitals and intensive-care settings. Demand is linked to emergency admissions, critical-care utilization, sepsis treatment, cardiovascular surgery, and anesthesia rather than elective outpatient prescribing.

When does Levophed lose exclusivity?

Levophed lost practical market exclusivity many years ago. The product was approved in the mid-20th century, and its active ingredient is now supplied by multiple generic manufacturers. The commercial question is not when Levophed's patent expires. It is whether any residual formulation, manufacturing, or regulatory protection can prevent generic substitution. In practice, those barriers are limited.

Levophed patent expiration and exclusivity timeline

Milestone	Approximate status
Original FDA approval	1950s
Active-ingredient exclusivity	Expired decades ago
Modern patent term	No relevant unexpired core patent identified
Generic availability	Established
FDA regulatory exclusivity	Expired
Current commercial protection	Brand recognition, supply reliability, hospital contracts

The Orange Book is the relevant FDA source for patents and regulatory exclusivity associated with approved drug products. Legacy norepinephrine injection products do not have the patent profile associated with newer small-molecule drugs or biologics [2].

What patents protect Levophed?

No material active patent estate is associated with the core Levophed product. The active ingredient, norepinephrine, is an old molecule. Any historical patents covering the compound or basic injectable use would have expired long ago.

Formulation patents

Norepinephrine injection products may differ in:

• Concentration
• Container and closure system
• Preservative status
• Ready-to-use versus concentrate presentation
• Diluent
• Stability characteristics
• Packaging and storage conditions

These distinctions can support product-specific regulatory filings or limited formulation patents, but they do not create broad protection over norepinephrine itself. A generic manufacturer can generally compete with an approved injectable product through an abbreviated new drug application if it demonstrates pharmaceutical equivalence and bioequivalence or satisfies the applicable injectable-drug requirements.

Method-of-use patents

The therapeutic uses of norepinephrine in hypotension, shock, and critical care are established clinical uses. No commercially significant method-of-use patent barrier is associated with Levophed's standard indications. Newer patents could theoretically cover a particular dosing protocol, coadministration method, or patient population, but such claims would not ordinarily block generic use of the basic injectable product.

Manufacturing and process protection

Manufacturing is more relevant than patent ownership. Sterile injectable production requires:

• Qualified aseptic filling capacity
• Validated sterilization and testing procedures
• Reliable active pharmaceutical ingredient supply
• Container-closure integrity controls
• Stability data
• FDA-compliant quality systems

These requirements can delay new entrants even when no patent blocks them. They do not provide Pfizer with conventional market exclusivity.

What is the FDA and Orange Book status of Levophed?

Levophed is an FDA-approved prescription injectable associated with Pfizer's NDA 007513. Generic norepinephrine products are approved through abbreviated or other applicable FDA pathways and compete with the reference product.

The FDA's Orange Book identifies approved drug products and associated patent or exclusivity information. For a legacy product such as Levophed, the relevant conclusion is that approval remains commercially useful, but regulatory approval does not create a continuing monopoly [2].

FDA regulatory considerations

Norepinephrine is a high-consequence hospital drug. Product quality failures or supply interruptions can have operational consequences for hospitals. FDA scrutiny therefore focuses on sterile manufacturing, contamination control, potency, labeling, and supply continuity.

The product's critical-care status can produce temporary commercial advantages for manufacturers with dependable inventory. Those advantages are operational, not patent-based.

How many patents cover Levophed?

The number of commercially meaningful active patents covering Levophed is effectively zero. Historical patent records may identify expired compound, formulation, or use patents, but expired rights do not prevent generic entry.

Protection category	Current competitive effect
Compound patent	None; expired
Core indication patent	None of practical significance
Brand trademark	Protects the Levophed name, not norepinephrine
Formulation patent	No broad blocking protection identified
Manufacturing patent	Potentially narrow and process-specific
Regulatory exclusivity	Expired
Trade secrets	Possible process value, but no product monopoly

The Levophed trademark can preserve brand recognition, but hospitals frequently purchase injectable drugs through formularies, group purchasing organizations, and institutional contracts. Brand identity has less pricing power in this setting than in outpatient specialty pharmaceuticals.

Which companies challenge Levophed through generic competition?

Generic competition comes from manufacturers of norepinephrine bitartrate injection and related ready-to-use presentations. The competitive field has included large injectable-drug suppliers and hospital-product manufacturers such as Pfizer's Hospira business, Fresenius Kabi, Hikma, Sandoz, and other FDA-approved suppliers, depending on the specific presentation and market period.

The relevant competitors are product-specific. A company may supply a 4 mg/4 mL vial, a different concentration, a premixed bag, or a ready-to-use syringe. These products can compete for the same clinical use while differing in packaging and purchasing economics.

Competitive factors

Factor	Importance
FDA approval	Required for hospital purchasing
Sterile capacity	High
Shortage history	High
Contract pricing	High
Product presentation	Moderate to high
Brand recognition	Moderate
Patent protection	Low
Switching cost	Moderate in hospital systems

What generic entry risks exist for Levophed?

Generic entry risk is already realized rather than prospective. Levophed competes in a mature generic market. The main risks to Pfizer are:

1. Substitution by lower-priced norepinephrine products.
2. Hospital formulary replacement.
3. Contract loss to generic injectable suppliers.
4. Price compression during competitive bidding.
5. Loss of share when hospitals standardize ready-to-use presentations.
6. Reduced relevance of the Levophed brand in institutional purchasing.

A generic manufacturer does not need to defeat a live composition-of-matter patent. It needs FDA approval, dependable production, acceptable quality metrics, and competitive pricing.

What is the investment case for Levophed?

Levophed is unlikely to be a standalone growth asset. Its investment value depends on the owner’s ability to monetize an established critical-care product without incurring disproportionate manufacturing or compliance costs.

Bull case

The positive scenario rests on supply scarcity and operating reliability:

• Persistent hospital demand for vasopressors
• Competitor shortages or manufacturing disruptions
• Stable or rising intensive-care utilization
• Higher demand for ready-to-use presentations
• Strong hospital contracts
• Efficient sterile manufacturing
• Limited short-term supplier capacity

In this scenario, a supplier can maintain revenue through volume, supply reliability, and product availability. The opportunity is strongest for a manufacturer with existing injectable infrastructure and a broad hospital portfolio.

Base case

The base case is a stable, low-growth generic hospital product:

• Demand remains clinically essential.
• Pricing remains competitive.
• Volume tracks hospital utilization.
• Revenue is broadly stable but lacks patent-driven expansion.
• Profitability depends on manufacturing efficiency and procurement contracts.
• Levophed remains strategically useful within a broader injectable portfolio.

Bear case

The downside scenario involves price erosion and supply-side execution problems:

• Additional generic entrants
• Loss of hospital contracts
• FDA warning letters or manufacturing remediation
• Sterile-facility shutdowns
• API supply disruption
• Higher quality-control costs
• Hospital conversion to competing presentations
• Declining contribution from the branded product

Because the molecule is old and widely understood, clinical differentiation provides little protection against these risks.

How much revenue exposure does Levophed create?

Public-company filings generally do not disclose Levophed revenue as a standalone line item. Pfizer reports revenue by broader business or product categories, and Levophed is not typically presented as a separately material revenue driver in the manner of its major patented medicines [3].

The product is therefore unlikely to move Pfizer's consolidated valuation materially. Its economic importance is more relevant at the business-unit level, especially for hospital injectable portfolios, supply agreements, and manufacturing utilization.

For a smaller generic manufacturer, norepinephrine can have greater relative importance. A critical-care injectable with recurring institutional demand can contribute useful portfolio stability, but revenue concentration becomes a risk if the company depends on a small number of products or facilities.

What patent litigation and Paragraph IV challenges affect Levophed?

No major patent litigation or commercially decisive Paragraph IV dispute is associated with the core Levophed product in the available public record. That outcome is consistent with the product's age and lack of meaningful unexpired core patents.

Paragraph IV litigation is primarily relevant when an ANDA applicant challenges listed patents in the Orange Book. With no significant blocking patent estate, generic competition is more likely to proceed through ordinary FDA approval and commercial contracting than through prolonged patent litigation.

The principal legal risks are instead:

• Product liability
• Manufacturing compliance
• Contract disputes
• Antitrust or procurement issues
• False-claim or promotional allegations
• Quality-related recalls

Does Levophed face biosimilar risk?

No. Levophed is a small-molecule chemical drug, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. The relevant competitors are generic norepinephrine products approved under FDA drug pathways, not biosimilars.

How does Levophed compare with competing vasopressors?

Drug	Role	Patent risk	Commercial profile
Levophed, norepinephrine	First-line vasopressor in many shock settings	Very low	Mature, hospital injectable
Vasopressin	Adjunct vasopressor	Low to moderate by formulation and use	Established critical-care product
Epinephrine	Vasopressor and resuscitation drug	Very low	Broad emergency use
Phenylephrine	Vasoconstrictor	Very low	Generic and hospital-focused
Angiotensin II	Vasodilatory shock treatment alternative	Higher than legacy agents	Specialty, differentiated product
Dopamine	Older vasopressor	Very low	Reduced use in some settings

Norepinephrine benefits from widespread clinical familiarity and guideline-supported use. Its disadvantage is commoditization. Newer agents can carry greater pricing power but usually address narrower populations and face more limited demand.

What geographic coverage does Levophed have?

Levophed's commercial reach is strongest in the United States, where Pfizer maintains the reference-brand position and where FDA-approved generic products compete. Norepinephrine injection is also marketed internationally under different brand names and generic labels, subject to local approvals, procurement systems, and national pricing controls.

Geographic expansion does not create meaningful patent value. In most jurisdictions, the active ingredient is long off-patent. Commercial performance depends on local hospital tenders, reimbursement, registration, manufacturing approvals, and distribution.

What manufacturing barriers protect norepinephrine suppliers?

The most important barrier is sterile injectable execution. A manufacturer must maintain:

• FDA-compliant aseptic operations
• Reliable norepinephrine API sourcing
• Validated filling and packaging lines
• Low particulate and contamination rates
• Stable inventory
• Regulatory inspection readiness
• Continuity plans for critical hospital products

These barriers can support temporary pricing and share advantages. They do not provide durable exclusivity. A facility disruption can reduce supply rapidly, but another approved supplier can capture demand once capacity is available.

Key Takeaways

• Levophed is Pfizer's branded norepinephrine bitartrate injection.
• The active ingredient and core clinical uses are long off-patent.
• No material current patent estate protects the core product.
• Generic entry is established, and Paragraph IV litigation is not the central risk.
• Levophed has no biosimilar exposure because it is a small-molecule drug.
• The commercial value comes from recurring hospital demand, supply reliability, and sterile manufacturing.
• Pfizer's consolidated revenue exposure is likely immaterial because the company does not report Levophed as a major standalone product.
• The strongest investment case is for an injectable manufacturer with efficient capacity and a broad critical-care portfolio.
• The main downside risks are price erosion, hospital contract losses, manufacturing failures, recalls, and supply disruption.
• Levophed is a defensive, mature hospital product rather than a patent-protected growth asset.

FAQs About Levophed Investment and Patent Risk

Is Levophed still a branded drug?

Yes. Levophed remains the reference brand for norepinephrine bitartrate injection, although hospitals can use FDA-approved generic equivalents.

Can a generic manufacturer launch norepinephrine without licensing Pfizer?

Generally, yes. Expired compound and regulatory protections do not require a generic manufacturer to obtain a Pfizer license. The manufacturer must obtain its own FDA approval and satisfy applicable quality requirements.

Is norepinephrine injection subject to drug shortages?

Norepinephrine and other sterile injectables have experienced supply disruptions in various periods. Shortage exposure depends on manufacturing capacity, API supply, facility events, recalls, and hospital demand. Shortages can temporarily improve supplier pricing and volume.

Does Levophed have pediatric exclusivity?

No current pediatric exclusivity right is associated with the mature Levophed product. Any historical exclusivity period would have expired.

Is Levophed a good acquisition target?

Levophed alone is unlikely to justify a high-growth valuation. It can be attractive as part of an acquisition of a hospital injectable portfolio, particularly where the buyer has underused sterile capacity, strong institutional contracts, or a strategy focused on critical-care supply reliability.

References

1. U.S. Food and Drug Administration. (2023). Levophed (norepinephrine bitartrate injection) prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. Pfizer Inc.